HUP0203746A2 - Új kompozíció és eljárás stabilizálására - Google Patents

Új kompozíció és eljárás stabilizálására

Info

Publication number
HUP0203746A2
HUP0203746A2 HU0203746A HUP0203746A HUP0203746A2 HU P0203746 A2 HUP0203746 A2 HU P0203746A2 HU 0203746 A HU0203746 A HU 0203746A HU P0203746 A HUP0203746 A HU P0203746A HU P0203746 A2 HUP0203746 A2 HU P0203746A2
Authority
HU
Hungary
Prior art keywords
group
carbon
atom
represent
lower alkyl
Prior art date
Application number
HU0203746A
Other languages
English (en)
Inventor
Tsuyoshi Habe
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22573018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0203746(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of HUP0203746A2 publication Critical patent/HUP0203746A2/hu
Publication of HUP0203746A3 publication Critical patent/HUP0203746A3/hu
Publication of HU229547B1 publication Critical patent/HU229547B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Abstract

A találmány olyan új kompozícióra vonatkozik, amely egy új biciklusosvegyületet és egy gliceridet tartalmaz. A találmány tárgya továbbáeljárás a biciklusos vegyület stabilizálására, amelynek lényege az,hogy a biciklusos vegyületet egy gliceriddel keverik össze. Atalálmány továbbá az új biciklusos vegyületekre vonatkozik, amelyek(I) általános képletében A jelentése -CH2OH, -COCH2OH vagy -COOHcsoport vagy ezek valamelyikének funkcionális származéka; X1 és X2hidrogénatomot, halogénatomot vagy rövid szénláncú alkilcsoportotjelentenek; V1 és V2 szénatomot vagy oxigénatomot jelentenek; továbbáW1 és W2 (III), (IV) vagy (V) képletű csoportot jelentenek, és az elsőkettőben R4 és R5 egymástól függetlenül hidrogénatomot, halogénatomot,hidroxilcsoportot, rövid szénláncú alkilcsoportot, rövid szénláncúalkoxicsoportot vagy hidroxi(rövid szénláncú)alkilcsoportot jelent,azzal a megkötéssel, hogy R4 és R5 egyidejű jelentésehidroxilcsoporttól vagy rövid szénláncú alkoxicsoporttól eltérő; Zjelentése szén-, oxigén-, kén- vagy nitrogénatom; R1 jelentésetelített vagy telítetlen, kétértékű rövid vagy közepes szénláncúalifás szénhidrogén-maradék, amely adott esetben szubsztituálva van;R2 jelentése telített vagy telítetlen, rövid vagy közepes szénláncúalifás szénhidrogén-maradék, amely adott esetben szubsztituálva van;vagy továbbá R2 jelentése rövid szénláncú cikloalkilcsoport, rövidszénláncú cikloalkoxicsoport, arilcsoport, ariloxicsoport,heterociklusos csoport vagy heterociklusos oxicsoport; és R3 jelentésehidrogénatom, rövid szénláncú alkilcsoport, rövid szénláncúcikloalkilcsoport, arilcsoport vagy heterociklusos csoport. Ó
HU0203746A 1999-10-15 2000-10-13 Novel composition and method for stabilizing the same HU229547B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15954999P 1999-10-15 1999-10-15
PCT/JP2000/007109 WO2001027099A2 (en) 1999-10-15 2000-10-13 Bicyclic compounds composition and method for stabilizing the same

Publications (3)

Publication Number Publication Date
HUP0203746A2 true HUP0203746A2 (hu) 2003-03-28
HUP0203746A3 HUP0203746A3 (en) 2005-02-28
HU229547B1 HU229547B1 (en) 2014-01-28

Family

ID=22573018

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0203746A HU229547B1 (en) 1999-10-15 2000-10-13 Novel composition and method for stabilizing the same
HU1300369A HU230484B1 (hu) 1999-10-15 2000-10-13 Egy biciklusos vegyületet és egy gliceridet tartalmazó új kompozíció

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU1300369A HU230484B1 (hu) 1999-10-15 2000-10-13 Egy biciklusos vegyületet és egy gliceridet tartalmazó új kompozíció

Country Status (26)

Country Link
US (5) US6583174B1 (hu)
EP (2) EP1426361B2 (hu)
JP (2) JP4332316B2 (hu)
KR (1) KR100830061B1 (hu)
CN (1) CN1268623C (hu)
AR (3) AR026046A1 (hu)
AT (2) ATE267189T1 (hu)
AU (2) AU780342B2 (hu)
BR (1) BRPI0014869B8 (hu)
CA (1) CA2385732C (hu)
CZ (1) CZ303625B6 (hu)
DE (2) DE60010913T2 (hu)
DK (2) DK1426361T4 (hu)
ES (2) ES2221859T3 (hu)
HK (2) HK1066792A1 (hu)
HU (2) HU229547B1 (hu)
IL (2) IL148803A0 (hu)
MX (1) MXPA02003756A (hu)
NO (1) NO330258B1 (hu)
NZ (1) NZ518020A (hu)
PT (2) PT1220849E (hu)
RU (1) RU2695274C3 (hu)
TR (1) TR200201032T2 (hu)
TW (1) TWI281918B (hu)
WO (1) WO2001027099A2 (hu)
ZA (1) ZA200202312B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221859T3 (es) * 1999-10-15 2005-01-16 Sucampo Ag Composicion de compuestos biciclicos y procedimiento para su estabilizacion.
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
EP1562604B1 (en) * 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
EP2281564A3 (en) * 2002-12-27 2012-09-05 Sucampo AG Derivatives of prostaglandins for treating abdominal discomfort
JP5294559B2 (ja) * 2003-07-03 2013-09-18 スキャンポ・アーゲー クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
TWI387454B (zh) 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
CN101198334B (zh) * 2005-04-12 2013-02-06 苏坎波公司 前列腺素化合物和质子泵抑制剂用于治疗肠胃病的联合应用
CN101466407B (zh) 2006-01-24 2013-05-15 株式会社·R-技术上野 包含双环化合物的药物组合物和使所述双环化合物稳定的方法
AU2007208632B2 (en) * 2006-01-24 2012-01-19 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
CN103804338A (zh) * 2006-02-07 2014-05-21 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
JP5390519B2 (ja) * 2007-07-19 2014-01-15 株式会社アールテック・ウエノ １１−デオキシ−プロスタグランジン化合物を含む医薬組成物およびその安定化方法
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
EP2460801B1 (en) 2009-07-28 2014-06-25 ONO Pharmaceutical Co., Ltd. Bicyclic compound and use thereof for medical purposes
CN104958298A (zh) * 2009-09-18 2015-10-07 阿得罗公司 阿片样受体拮抗剂用于胃肠道疾病的用途
CA2779736A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
JP5907077B2 (ja) 2011-01-27 2016-04-20 小野薬品工業株式会社 二環式化合物およびその医薬用途
EP2669279B1 (en) 2011-01-27 2017-01-11 ONO Pharmaceutical Co., Ltd. Bicyclic compound and use thereof for medical purposes
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
EP3277274A4 (en) 2015-04-01 2018-12-05 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
ES2890989T3 (es) 2016-06-30 2022-01-25 Ono Pharmaceutical Co Método para producir un compuesto bicíclico
US11534404B2 (en) 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
JPWO2019221215A1 (ja) * 2018-05-18 2021-05-27 ニプロ株式会社 ルビプロストン含有粒子状医薬組成物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18202A (en) * 1857-09-15 Improvement in feathering paddle-wheels
JPS5720305B2 (hu) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
US3966962A (en) * 1975-03-27 1976-06-29 The Upjohn Company Triacetin solutions of PGE-type compounds
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5919524B2 (ja) 1976-12-17 1984-05-07 中外製薬株式会社 安定な１α−ヒドロキシビタミンＤ類含有製剤
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
CA1184906A (en) * 1977-04-19 1985-04-02 Roy A. Johnson 9-deoxy-5,9-epoxy-prostaglandins
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
JPS5452717A (en) * 1977-09-29 1979-04-25 Chugai Pharmaceut Co Ltd Stable oily pharmaceuticals containing 1alpha-hydroxyvitamin d
US4130566A (en) * 1977-10-27 1978-12-19 Sumitomo Chemical Company, Limited Process for producing 5-carboxy-2-acetylthiophene
AT358530B (de) 1978-04-25 1980-09-10 Plc Pharma Licences Stabilisierungsverfahren
JPS55136219A (en) 1979-04-11 1980-10-23 Sumitomo Chem Co Ltd Diazepam oily drug
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
JPS59137413A (ja) * 1983-01-25 1984-08-07 Teijin Ltd ７−チアプロスタグランジンｅ↓１類を含有する医薬品組成物
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US4758880A (en) 1987-03-27 1988-07-19 The Grass Valley Group, Inc. Video matte generator
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ES2051862T3 (es) 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JP2597649B2 (ja) † 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
EP0347243B1 (en) * 1988-06-17 1993-01-13 The Wellcome Foundation Limited Prostaglandin analogues for use in medicine
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
JPH0745504B2 (ja) 1988-07-29 1995-05-17 株式会社上野製薬応用研究所 プロスタグランジン前駆体およびその製法
JP2794433B2 (ja) 1989-02-02 1998-09-03 丸善製薬株式会社 甘草疎水性フラボノイド製剤
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2030346C (en) † 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030344C (en) † 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2041417C (en) 1990-05-01 2002-05-21 Ryuji Ueno Treatment of pancreatic disease with 15-keto-prostaglandin compounds
JPH0446122A (ja) 1990-06-13 1992-02-17 Nippon Iyakuhin Kogyo Kk 活性型ビタミンｄ↓３類含有製剤
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
JP2746800B2 (ja) * 1991-09-03 1998-05-06 株式会社アールテック・ウエノ プロスタグランジン中間体の製法
US5274130A (en) * 1991-09-03 1993-12-28 R-Tech Ueno Ltd. Process for production of prostaglandin intermediates
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
ES2221859T3 (es) * 1999-10-15 2005-01-16 Sucampo Ag Composicion de compuestos biciclicos y procedimiento para su estabilizacion.
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4210631B2 (ja) 2004-06-24 2009-01-21 株式会社日立製作所 ブレーキ制御装置

Also Published As

Publication number Publication date
HU229547B1 (en) 2014-01-28
DK1426361T4 (en) 2015-03-16
AU780342B2 (en) 2005-03-17
EP1220849B1 (en) 2004-05-19
EP1426361B2 (en) 2015-02-25
AU2004242503C1 (en) 2005-01-27
CZ303625B6 (cs) 2013-01-16
KR100830061B1 (ko) 2008-05-16
PT1220849E (pt) 2004-10-29
TWI281918B (en) 2007-06-01
US20080255227A1 (en) 2008-10-16
CZ20021037A3 (cs) 2002-09-11
IL148803A0 (en) 2002-09-12
DE60010913T2 (de) 2005-06-09
HUP0203746A3 (en) 2005-02-28
US20120095090A1 (en) 2012-04-19
US7417067B2 (en) 2008-08-26
ATE402925T2 (de) 2008-08-15
US8097649B1 (en) 2012-01-17
ZA200202312B (en) 2002-12-24
JP2009235079A (ja) 2009-10-15
RU2695274C9 (ru) 2020-01-22
WO2001027099A3 (en) 2001-10-25
AU2004242503A1 (en) 2005-01-27
DK1220849T3 (da) 2004-09-27
AR089848A2 (es) 2014-09-24
EP1220849A2 (en) 2002-07-10
ES2309410T3 (es) 2008-12-16
US6583174B1 (en) 2003-06-24
RU2002112984A (ru) 2004-01-20
HK1045693B (zh) 2005-01-21
ES2309410T5 (es) 2015-03-17
MXPA02003756A (es) 2005-09-08
BR0014869A (pt) 2002-06-25
US20040235885A1 (en) 2004-11-25
WO2001027099A2 (en) 2001-04-19
NO20021736L (no) 2002-04-12
BRPI0014869B1 (pt) 2017-06-13
RU2695274C3 (ru) 2020-11-09
DE60039727D1 (de) 2008-09-11
AU7685600A (en) 2001-04-23
DE60010913D1 (de) 2004-06-24
AU2004242503B2 (en) 2007-06-21
BRPI0014869B8 (pt) 2021-05-25
HK1066792A1 (en) 2005-04-01
KR20020068521A (ko) 2002-08-27
ES2221859T3 (es) 2005-01-16
HU230484B1 (hu) 2016-07-28
RU2695274C2 (ru) 2019-07-22
CA2385732A1 (en) 2001-04-19
NO330258B1 (no) 2011-03-14
IL148803A (en) 2006-07-05
HUP1300369A2 (hu) 2003-03-28
TR200201032T2 (tr) 2002-08-21
NZ518020A (en) 2004-02-27
PT1426361E (pt) 2008-10-08
HK1045693A1 (en) 2002-12-06
ATE267189T1 (de) 2004-06-15
AR109354A2 (es) 2018-11-21
EP1426361B1 (en) 2008-07-30
JP2003511445A (ja) 2003-03-25
AR026046A1 (es) 2002-12-26
CN1268623C (zh) 2006-08-09
JP4332316B2 (ja) 2009-09-16
NO20021736D0 (no) 2002-04-12
US8088934B2 (en) 2012-01-03
CN1379769A (zh) 2002-11-13
DK1426361T3 (da) 2008-11-17
EP1426361A1 (en) 2004-06-09
CA2385732C (en) 2009-02-10

Similar Documents

Publication Publication Date Title
HUP0203746A2 (hu) Új kompozíció és eljárás stabilizálására
PL348769A1 (en) 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
CA2184919A1 (en) New Piperazine Derivatives and Methods for the Preparation Thereof and Compositions Containing the Same
UA41290C2 (uk) Гетероариламіни, фармацевтична композиція, спосіб інгібування холінестерази у ссавців, спосіб покращення пам'яті
ES8700930A1 (es) Procedimiento de preparacion de una composicion cosmetica en emulsion que contiene una sulfonamida derivada del 3-bencilideno-alcanfor.
AU3464297A (en) Piperazine derivatives and process for the preparation thereof
DE3876813T2 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
MY144529A (en) Additive mixtures
MX9706014A (es) Derivados de xanteno y acridina y su empleo.
DE69820481D1 (de) Verfahren zur herstellung von cholecalciferol-derivaten und zwischenverbindungen
DE60000978T2 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
ATE261441T1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
BR9813923A (pt) N n - bis(sulfonil) hidrazinas úteis como agentes antineoplásicos
DE59203777D1 (en) Aminomethylencyanessigsäureester und -amide.
GB2044614B (en) Therapeutic compositions with a cytostatic action
ATE154359T1 (de) 2'-methylidenpyrimidinnukleosidverbindungen, ihre verwendung und verfahren zu ihrer herstellung
AU3350195A (en) Bicyclic carboxamides as 5-HT-1A antagonists
WO1999065864A3 (de) Geminal substituierte amine
DE60007848D1 (de) Herstellung von 2'-substitutierter rns
HUP0202335A2 (hu) Eljárás optikailag aktív, vinil-szubsztituált ciklopropánkarbonsavak racemizálására
BG100704A (en) New piperazine derivatives and methods for their preparation as well as of the compounds containing them
CO4940468A1 (es) Nuevos derivados de naftilpiperacina
DE3667992D1 (de) Verfahren zum stabilisieren von organopolysiloxanen.
PH21576A (en) Novel n-nitroso compounds, compositions containing such compounds, and methods of treatment therewith
ATE31404T1 (de) Verfahren zur herstellung von cycklopropanabkoemmlingen.

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees